Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1982 Feb;27(2):129-38.
doi: 10.1007/BF01311706.

Circulating immune complexes in Crohn's disease. Their characterization and interrelationship with components of the complement system

Circulating immune complexes in Crohn's disease. Their characterization and interrelationship with components of the complement system

E R Richens et al. Dig Dis Sci. 1982 Feb.

Abstract

Of the sera from 55 patients with Crohn's disease, 37% showed evidence of anticomplementary activity, C3 and C4 levels were significantly increased in these patients compared with control subjects, although total hemolytic complement levels were normal. C3 inactivation products were demonstrated in 32.9% of serum and plasma samples from 51 patients with CD. This was taken to be evidence of in vivo activation of C3 and the complement system. Activation of the C' system was thought to be caused by circulating immune complexes since evidence of anticomplementary activity could be correlated with incidence of C3 activation. Gel filtration studies carried out on 15 serum samples (13 patients) showing anticomplementary activity showed this activity to be confined to two fractions of molecular weight range greater than 10(6) and 2 x 10(5) - 10(6) daltons. IgG and IgA were present in both these fractions. As the molecular weights of IgG and IgA are lower than the molecular weight range of these fractions, it is possible that the immune complexes were composed of IgG and possibly IgA complexed with antigen.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Lancet. 1974 May 25;1(7865):1014-7 - PubMed
    1. Clin Exp Immunol. 1977 Jun;28(3):490-5 - PubMed
    1. Clin Exp Immunol. 1973 Jun;14(2):219-26 - PubMed
    1. Clin Exp Immunol. 1978 Jan;31(1):81-91 - PubMed
    1. Clin Exp Immunol. 1975 Nov;22(2):197-209 - PubMed

Publication types